Opinion of the safety of glucosamine hydrochloride from Aspergillus niger as food ingredient

EFSA Journal

Volumn 7, Issue 6, 2009, Pages

[No Author Info available]

Author keywords

Aspergillus niger; Glucosamine; ingredient; novel food

Indexed keywords

EID: 85078374135     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2009.1099     Document Type: Article

References (44)

1. Aghazadeh-Habashi A and Sattari S, 2002. Single dose pharmacokinetics and bioavailability in the rat. J. Pharm. Pharmaceut. Sci. 5, 181–184.
2. Albert SG, Oiknine RF, Parseghian S, Mooradian AD, Haas MJ and McPherson T, 2007. The effect of glucosamine on serum HDL cholesterol and apolipoprotein A*1 levels in people with diabetes. Diabetes Care, 30 (11), 2800–3.
3. Anderson JW, Nicolosi R J and Borzelleca JF, 2005. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food and Chem. Toxicol. 43, 187–201.
4. Bannerjee G and Manna GK, 1984. Bone marrow chromosome aberration in mice injected with an antimetabolite, D-glucose amine hydrochloride. In Manna GK and Sinka U (Eds) Perspectives in Cytology and Genetics: Proc. Fourth All India Congress of Cytology and Genetics, 1981. Kalyani, India. Bhagalpur University, India, 1984, pp 377–382.
5. Beren J, Hill SI, Siener-West M and Rose NR, 2001. Effect of pre-loading oral glucosamine HCl/chondroitin sulphate/manganese ascorbate combination of experimental arthritis in rats. Proc. Soc. Exper. Biol. Med., 226, 144–151.
6. Biggee BA and McAlindon T, 2004. Glucosamine for osteoarthritis: Part I, review of the clinical evidence. Medicine and Health, Rhode Island, 87, 176–179.
7. Biggee BA, Blinn CM, Nuite M, Silbert JE and McAlindon TE, 2007. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann. Rheum. Dis., 66, 260–262.
8. Brusick DJ, Simmons VF, Rosenkrantz HS, Ray VA and Stafford RS, 1980. An evaluation of the Escherichia coli WP2 and WP2 UVRA reverse mutation assay. Mutation Res., 76, 169–190.
9. Caron JP, Peters TL, Hauptman JG, Eberhart SW and Orth MW, 2002. Serum concentrations of kertatan sulphate, osteocalcin and pyridinoline crosslinks after oral administration of glucosamine to standard-bred horses during race training. Amer. J. Vet. Res., 63, 1106–1110.
10. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW and Williams HJ., 2006. Glucosamine chondroitin sulphate and the two in combination for painful knee osteoarthritis. N. Engl. J. Med., 354, 795–808.
11. Dahmer S and Schiller RM, 2008. Glucosamine. Am. Fam. Physician, 78 (4), 471–6.
12. Echard BW, Talpur NA, Funk KA, Bagchi D and Preuss HG, 2001. Effects of oral glucosamine and chondroitin sulphate alone and in combination in the metabolism of SHR and SD rats. Molec. Cell. Biochem., 225, 85–91.
13. Fenton JI, Orth MW, Chlebeck-Brown KA, Neilson BD, Corn CD, Waite KS and Caron JP, 1999. Effect of longeing and glucosamine supplementation on serum markers of bone and joint metabolism in yearling quarter horses. Canad. J. Vet. Res., 63, 288–291.
14. FSA, 2009. Food Standards Agency, Committee on Toxicity (CoT) Statement on glucosamine and hepatotoxicity. COT statement 2009/01 April 2009.
15. Hanson RR, Smalley LR, Huff GK, White S and Hammad TA, 1967. Oral treatment with a glucosamine-chondroitin sulphate compound for degenerative joint disease in horses: 25 cases. Equine Practice, 19, 16–22.
16. Heart E, Choi WS and Sung CK, 2000. Glucosamine-induced insulin resistance in 3T3-L1 adipocytes. Amer. J. Physiol. Endocrin. Metab., 278, E101–E112.
17. IOM, 2003. Safety review: Draft 3 Prototype Monograph on Glucosamine. Institute of Medicine (IOM). National Academy of Sciences (NAS), Washington, DC., 2003, pp 1–84.
18. Lee KY, Shibutani M, Takagi H, Arimura T, Takigami S, Uneyama C, Kato N and Hirose M, 2004. Subchronic toxicity study of dietary N-acetylglucosamine in F344 rats. Food and Chem. Tox., 42, 687–695.
19. Leuschner F and Neumann BW, 1987. Laboratorium fur Pharmakologie and Toxicologie Report, Hamburg, FRG: Aug. 4, 1987 (Unpublished study). Cited in Setnikar et al., 1991.
20. Marshall PD, Poddar S, Tweed EM and Brandes L, 2006. Clinical inquiries: Do glucosamine and chondroitin worsen blood sugar control in diabetes? J. Fam. Pract., 55 (12), 1091–3.
21. McNamara PS, Barr SC and Erb HN, 1996. Hematologic, hemostatic and biochemical effects in dogs receiving an oral chondroprotective agent for thirty days. Amer. J. Vet. Res., 57, 1390–1394.
22. Mecchi MS, 2003. Salmonella-Escherichia Coli/Mammalian-Microsome Reverse Mutation Assay with Cargill Glucosamine Hydrochloride. Covance Laboratories, Inc., Vienna, Virginia., Report 7178–124, 1–24, 4-23-2003.
23. Monauni T, Zenti MG, Cretti A, Daniels MC, Targher G, Caruso B, Caputo M, McClain D, Del Prato S, Giaccari A, Muggeo M, Bonora E and Bonadonna RC, 2000. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes, 49, 926–935.
24. Muniyappa R, Karne RJ, Hall G, Crandon SK, Bronstein JA, Ver MR, Hortin GL and Quon MJ, 2006. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes, 55, 3142–3150.
25. Nanjou S, Fuii S, Tanaka K, Ueda K and Komona T, 1984. Induction of strand breakage in F174 RFI DNA by amino sugar derivatives. Agricult. Biol. Chem., 48, 2865–2867.
26. Nelson BA, Robinson KA and Buse MG, 2000. High glucose and glucosamine induce insulin resistance via different mechanisms in 3T3-L1 adipocytes. Diabetes, 49, 981–991.
27. Pham T, Cornea A, Blick KE, Jenkins A and Scofield RH, 2007. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am. J. Med. Sci., 333 (6), 333–9.
28. Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits P and Tack CJ, 2001. Short-term glucosamine infusion does not affect insulin sensitivity in humans. J. Clin. Endocrinol. Metab., 86, 2099–2103.
29. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE and Gossett C, 2001. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized placebo-controlled clinical trial. Lancet, 357, 251–256.
30. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y and Reginster JY, 2003. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch. Internal Medicine, 163, 1514–1522.
31. Schuster E, Dunn-Coleman N, Frisvad JC and Van Dijck PW, 2002. On the safety of Aspergillus niger – a review. Appl. Microbiol. Biotech., 59, 426–435.
32. Scroggie DA, Albright A and Harris MD, 2003. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blind, randomized clinical trial. Arch. Intern Med., 163 (13), 1587–90.
33. Setnikar I, Giacchetti C and Zanolo G, 1986. Pharmacokinetics of glucosamine in the dog and man. Arzneimittal-Forschung, 36, 729–735.
34. Setnikar I, Pacini MA and Revel L, 1991. Antiarthritic effects of glucosamine sulphate studied in animal models. Arzneimittal-Forschung, 41, 542–545.
35. Setnikar I, Palumbo R, Canali S and Zanolo G, 1993. Pharmacokinetics of glucosamine in man. Arzneimittal-Forschung, 41, 1109–1113.
36. Setnikar I and Rovati LC, 2001. Absorption, distribution, metabolism and excretion of glucosamine sulphate. A review. Arzneimittal-Forschung, 51, 699–725.
37. Stender S and Astrup P, 1977. Glucosamine and experimental atherosclerosis. Increased wet weight and changed composition of cholesterol fatty acids in aorta of rabbits fed a cholesterol-enriched diet with added glucosamine. Atherosclerosis, 26, 205–213.
38. Stumpf JL and Lin SW, 2006. Effects of glucosamine on glucose control. Ann. Pharmacother, 40, 690–698.
39. Sugimura T, Birnbaum SM, Winitz M and Greenstein JP, 1959. Quantitative nutritional studies with water-soluble, chemically defined diets. IX D-glucosamine-containing diets. Arch. Biochem. Biophys., 83, 521–527.
40. Tannis AJ, Barban J and Conquer JA, 2004. Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage, 12, 506–511.
41. Towkeed TE, Anastassiaides TP, Shea B, Houpt J, Welch V and Hochberg MC, 2005. Glucosamine therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews, Issue 2. Art. No: CD002946. DOI: 10.1002/14651858.
42. Uldry M, Ibberson M, Hosokawa M and Thorens B, 2002. GLUT2 is a high affinity glucosamine transporter. FEBS Letters, 524, 199–203.
43. Yu JG, Boies SM and Olefsky JM, 2003. The effect of oral glucosamine sulphate on insulin sensitivity in human subjects. Diabetes Care, 26, 1941–1942.
44. Zhou J, Waszkuc T and Mohammed F, 2005. Determination of Glucosamine in Raw Materials and Dietary Supplements Containing Glucosamine Sulfate and/or Glucosamine Hydrochloride by High-Performance Liquid Chromatography with FMOC-Su Derivatization. J. AOAC International: 88 (4): 1048–1058.